Ceryvyn Advances LAM Drug Program, Cash Falls To $28 Million
CYV: $0.010 +0.00% · MC: $12M
Ceryvyn Therapeutics says preclinical and inhalation studies for its LAM drug candidate remain on track, and it has contracted to use Xe-MRI in a planned early signal-finding study; an advisory board supported the approach, subject to Stage 1 preclinical requirements. Cash and equivalents fell to approximately $28 million from $30 million at the prior quarter-end, while quarterly operating cash outflow increased from the previous quarter. The company has selected a contract research organisation for the next development stage, with study scope and agreements still to be finalised.

Comments